Amy Ripka

Chief Executive Officer Amy has over 20 years of drug discovery experience and was involved in the discovery of two marketed drugs (Daklinza® and Sunvepra®). She has participated in 5 biotech INDs and has more than 30 issued patents. She has held VP and Executive Director positions at prominent CROs. Amy has chaired the prestigious Medicinal Chemistry Gordon Conference and currently serves on the Scientific Advisory Boards of Q Biomed Ventures and Rheostat Therapeutics.